pyrazines has been researched along with Hyperthyroid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braverman, LE; Farber, HW; Menon, AA; Sahay, S | 1 |
| Cho, JH; Huh, KB; Kim, KR; Lee, EJ; Lee, HC; Lim, SK; Nam, MS; Nam, SY; Song, YD | 1 |
| Cho, BY; Kim, CH; Kim, SY; Lee, HK; Lee, MK; Park, DJ; Park, KS; Shin, CS | 1 |
1 trial(s) available for pyrazines and Hyperthyroid
| Article | Year |
|---|---|
Acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid levels in hyperthyroidism.
Topics: Administration, Oral; Adult; Fatty Acids, Nonesterified; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hyperthyroidism; Hypolipidemic Agents; Male; Pyrazines | 1995 |
2 other study(ies) available for pyrazines and Hyperthyroid
| Article | Year |
|---|---|
Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway.
Topics: Acetamides; Adult; Aged; Antihypertensive Agents; Epoprostenol; Female; Goiter; Graves Disease; Hashimoto Disease; Humans; Hyperthyroidism; Male; Pulmonary Arterial Hypertension; Pyrazines; Thyroiditis, Autoimmune; Thyrotoxicosis | 2019 |
Metabolic effect of decreasing nonesterified fatty acid levels with acipimox in hyperthyroid patients.
Topics: Administration, Oral; Adult; Blood Glucose; Body Mass Index; Fatty Acids, Nonesterified; Glucose Tolerance Test; Humans; Hyperthyroidism; Hypolipidemic Agents; Male; Pyrazines; Reference Values; Thyrotropin; Thyroxine; Triiodothyronine | 1999 |